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Muscular dystrophyes encoding proteins involved in α-dystroglycan glycosylation result in
dystroglycanopathies: severe congenital muscular dystrophy phenotypes often accompanied by CNS
abnormalities and ocular defects. We have identiﬁed the zebraﬁsh orthologues of the seven known genes
in this pathway and examined their expression during embryonic development. Zebraﬁsh Large, POMT1,
POMT2, POMGnT1, Fukutin, and FKRP show in situ hybridization patterns similar to those of dystroglycan, with
broad expression throughout early development. By 30 h postfertilization (hpf), transcripts of all these genes
are most prominent in the CNS, eye, and muscle, tissues that are predominantly affected in the
dystroglycanopathies. In contrast, Large2 expression is more restricted and by 30 hpf is conﬁned to the
lens, cerebellum, and pronephric duct. We show that the monoclonal antibody IIH6, which recognizes a
glycoform of dystroglycan, also detects the zebraﬁsh protein. Injection of morpholino oligonucleotides
against zebraﬁsh Large2 resulted in loss of IIH6 immunostaining. These data indicate that the dystroglycan
glycosylation pathway is conserved in zebraﬁsh and suggest this organism is likely to be a useful model
system for functional studies.
© 2008 Elsevier Inc. All rights reserved.Glycosylation is an important but poorly understood posttransla-
tion modiﬁcation implicated in many biological processes, including
development, immunology, and cell recognition. It has been estimated
that 1% of human genes encode enzymes involved in oligosaccharide
synthesis and function [1]. Mutations in six human genes encoding
proteins known or predicted to be involved in glycosylation processes
(POMT1, POMT2, POMGnT1, Fukutin, FKRP, and LARGE) have been
shown to produce severe congenital muscular dystrophy (CMD)
phenotypes [2,3]. These dystrophies are often accompanied by
neuronal migration abnormalities, cardiomyopathy, and ocular
defects [2,3]. Mutation of the mouse orthologue of Large results in a
muscular and neuronal phenotype (the Largemyd mutant) that shows
many similarities to these CMDs [4,5].
These forms of muscular dystrophy are collectively termed
“dystroglycanopathies” as they are all associated with hypoglycosyla-
tion of α-dystroglycan (α-DG), a key component of the dystrophin-
associated glycoprotein complex (DGC). In skeletal muscle the DGC
links cytoskeletal actin to laminin in the extracellular matrix [6].
However, the DGC is also found in many other tissues and cell types,
including brain, peripheral nerve, and kidney, where it contributes to
processes such as neuronal migration and basement membranewith the GenBank Data Library
(FKRP), DQ826747 (POMGnT1),
ewitt).
l rights reserved.formation [7]. In mice, null mutations for dystroglycan (Dag1) display
early embryonic lethality [8].
In the dystroglycanopathies, a hypoglycosylated form of α-DG is
produced that is deﬁcient in binding to extracellular matrix ligands
such as laminin and agrin [5,9]. A key role forα-DG in the pathological
mechanism of these disorders is supported by gene knockout studies
in mice. Selective deletion of dystroglycan in the CNS produces brain
abnormalities similar to those seen in the human disorders and the
Largemyd mouse [10], while deﬁciency in skeletal muscle results in a
progressive muscular dystrophy [11].
Dystroglycan is synthesized as a precursor protein that is
posttranslationally cleaved into α and β subunits [6]. α-DG has an
apparentmolecularmass varying from120 kDa in brain and peripheral
nerve to N150 kDa in skeletal and cardiacmuscle, due to tissue-speciﬁc
differences in the extent and type of glycosylation [6]. The protein
contains a central mucin-like domain that undergoes extensive O-
glycosylation, including the addition of unusual O-mannosyl-type
oligosaccharide structures [12]. O-mannosylation is rare in mammals
and has been identiﬁed in only a limited number of glycoproteins
(including dystroglycan) in brain, nerve, and skeletal muscle [12].
Several of the genes implicated by genetic studies to be required for
functional dystroglycan glycosylation have biochemical activities that
are involved in biosynthesis of O-mannose glycans. POMT1 and POMT2
encode protein O-mannosyltransferases, appearing to function as a
complex [13]. POMGnT1 encodes the protein O-linked mannose β1,2-
N-acetylglucosaminyltransferase, which transfers N-acetylglucosa-
mine from UDP-GlcNAc to O-mannosyl glycoproteins, thus acting
Table 1
Dystroglycanopathy-associated genes
Gene Organism Gene size (kb) Genomic location (Mb)
FKRP Human 2 Chr 19q13.32 (51.9)
Zebraﬁsh 2 Chr 15 (26.6)
Fukutin Human 60 Chr 9q31.2 (107.4)
Zebraﬁsh 12 Chr 5 (78.5)
POMGnT1 Human 9 Chr 1p34.1 (46.4)
Zebraﬁsh 17 Chr 6 (69.0)
POMT1 Human 19 Chr 9q34.13 (134.4)
Zebraﬁsh 20 Chr 5 (56.3)
POMT2 Human 43 Chr 14q24.3 (76.8)
Zebraﬁsh 15 Chr 14 (39.2)
The gene sizes and genomic locations of the human and zebraﬁsh dystroglycanopathy-
associated genes are presented. Zebraﬁsh gene locations are according to Ensembl
version 40.
160 C.J. Moore et al. / Genomics 92 (2008) 159−167downstream of POMT1. However, the biochemical functions of
Fukutin, FKRP, and Large are currently unknown.
The use of mice for genetic dissection of this glycosylation pathway
is both time consuming and expensive. Furthermore, because Fukutin,
Dag1, and POMT1 null mutations in mice all result in embryonic
lethality [8,14,15], it has proved difﬁcult to study the roles of α-DG
glycosylation in muscular dystrophies through this approach. The
zebraﬁsh is an attractive alternative model system for investigation of
the functional relationships between these genes, especially during
early development. An advantage over the mouse is that in zebraﬁsh,
basement membrane formation is not a crucial step until organogen-
esis is under way [16], therefore early embryonic development is not
as severely affected by loss of basement membrane as it is in mice.
Muscle structure and embryonic studies are also well suited to
zebraﬁsh due to their translucent early developmental stages and the
high proportion of muscle tissue in embryos [17]. DGC has been well
characterized in zebraﬁsh [18–20] and morpholino oligonucleotide
(MO) knockdowns or mutants have been produced for dystrophin
[21], dystroglycan [16], and laminins β1 and γ1 [22,23]. In addition,Fig. 1. Zebraﬁsh and human gene structures. Stick and block representations of the exon/intro
UTRs and start and stop codons are marked on the genes, scale bars are shown to the righ
alternative splice products for the 5′UTR of zebraﬁsh POMT2 were identiﬁed; however, thesthis organism is particularly suited to large-scale screens for modiﬁer
genes and testing of potential therapeutic reagents [24].
We have previously shown that Large and its vertebrate paralogue
Large2 are conserved in zebraﬁsh [25]. Here we show that the other
known members of this pathway are also conserved in this species,
indicating that the zebraﬁsh is likely to be a useful model organism for
future functional studies of these genes.
Results
Identiﬁcation of dystroglycanopathy genes in zebraﬁsh
Genes were identiﬁed by TBLASTN searches of the zebraﬁsh
genome assembly and EST databases with the human amino acid
sequence followed by detailed analysis of genomic hits. Single
orthologues were identiﬁed for all of the genes investigated (POMT1,
POMT2, POMGnT1, Fukutin, and FKRP; Table 1). We carried out a
phylogenetic analysis of the POMT1 and POMT2 proteins to conﬁrm
the gene assignments as they are very closely related. An unrooted
neighbor-joining tree is shown in Supplemental Fig. 1. The POMT1 and
POMT2 proteins form two distinct groups that are well separated in
the tree by a long branch, conﬁrming the correct classiﬁcation of the
zebraﬁsh genes.
EST analysis and RT-PCR were used to conﬁrm the exon structure
and the coding sequence of each gene. The structures of the zebraﬁsh
genes are compared to those of their human orthologues in Fig. 1. The
coding exon size and splice site locations are generally well conserved
between human and zebraﬁsh. However, there is very little conserva-
tion of intron sizes and UTRs; for example, zebraﬁsh Fukutin( fktn) and
POMT2 both have much smaller 3′UTRs than their corresponding
human genes. We conﬁrmed that the zebraﬁsh 3′UTR spans at least
700 bp by RT-PCR (primer sequences are provided in Table 2). As there
are three potential poly(A) adenylation sites within this 700-bp
region, theremay be alternative 3′ ends of themRNA. This predicted 3′
UTR also contains a short interspersed nuclear element and an ANGEL
transposon element.n structures of human and zebraﬁsh FKRP, Fukutin, POMGnT1, POMT1, and POMT2 genes.
t of each gene. For POMT1 both the human and the zebraﬁsh use the same scale. Two
e do not alter the amino acid sequence of the protein.
Fig. 2. Expression of dystroglycanopathy genes in zebraﬁsh. Representative 2% agarose
gels of RT-PCR products for zebraﬁsh Fukutin, FKRP, Large, Large2, POMGnT1, POMT1,
POMT2, and Ef1α using RNA from different developmental stages are shown. Sizes of
products and selected marker sizes are indicated. HLIV, Hyperladder IV DNA molecular
weight marker (Bioline); −, negative control with water replacing template.
Table 2
PCR primers used for RT-PCR and generation of in situ probes
Gene Name Sequence 5′–3′ Ta°C Product
(bp)
Large (RT-PCR) zLarge_f1 GGGCGCAGGAAGTTTGTG 58 180
zLarge_r1 CCGGAGCCTCAGCTCTAAA
Large (in situ probe) zLarge_f1 GGGCGCAGGAAGTTTGTG 60 764
zLarge_r2 TTGTGGAAGACGACCCACAG
Large2 (RT-PCR) zLarge2_f1 CCTGTCGAGGGAAGCTGAAG 58 186
zLarge2_r1 CCACTTCACGAACCCTTGAT
Large2 (in situ probe) zLarge2_f1 CCTGTCGAGGGAAGCTGAAG 60 679
zLarge2_r2 GAAAGGTTGGATGGCAGAGC
Fukutin (RT-PCR) zFukutin_2f CTGACTCCATTATCAACCAG 60 202
zFukutin_2r GTAGACCATCCTTCCCACCA
Fukutin (in situ probe) zFukutin_f CGGCCTGGTCCACAAGTTTA 60 1189
zFukutin_r TCCATTCCAGACCACGTCAC
FKRP (RT-PCR) zFKRP_f GGGTATCCCGTCAAAAGGAA 58 186
zFKRP_r GTCAGCTGATCCCATTCAGG
FKRP (in situ probe) zFKRP_2f GTGCAGTGCCTTCATCTTCG 60 1068
zFKRP_2r TCCCAAACAATGCACACACA
FKRP (RT-PCR) zFKRP_2f GTCAAAACCTGGGACTGGAA 58 637
zFKRP_4r AAACGGCATTGAAGTGGTTTA
POMGnT1 (RT-PCR) zPOMGnT1_f ATGGACACCTGGACACCAAA 58 219
zPOMGnT1_r TTCTTGAGCCGCATCATCTT
POMGnT1 (in situ
probe)
zPOMGnT1_2f AGCCGCTCCAAGGTGTATGT 60 1097
zPOMGnT1_2r TTCTCAGGAGTCGGCATTT
POMT1 (RT-PCR) zPOMT1_f GCACTCGTGGTGCTACCTGT 58 198
zPOMT1_r GGAGACTGTGCGGAGAGTGA
POMT1 (in situ probe) zPOMT1_2f GGCATTCACTTTCCCAAAGC 55 999
zPOMT1_2r GGGCTGCTGACCACAAGACT
POMT2 (RT-PCR) zPOMT2_f GCCTCTCTGGGTCTCTTGGT 58 200
zPOMT2_r TGAATGGCGAATATTGTCGTG
POMT2 (in situ probe) zPOMT2_2f ACGATGTTGAACACCACCAG 58 2491
zPOMT2_2r CCTTCAACACGGAAATGTCA
EF1α (RT-PCR) EF1α_f2 CAGCTGATCGTTGGAGTCAA 62 208
EF1α_r2 TCTTCCATCCCTTGAACCAG
The primers used in RT-PCR and for generation of in situ hybridization probes, with
annealing temperature (Ta°C) and product size, are indicated.
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We ﬁrst used RT-PCR analysis of these genes and also of Large and
Large2 to establish the developmental stages at which they are
expressed. The ubiquitously expressed transcription factor EF1α [26]
was used as a positive control. The sequences of the primers used are
listed in Table 2. Transcripts from all the genes were ampliﬁed at the 1-
cell stage, although expression of Large, and especially Large2,
appeared weak (Fig. 2). Zygotic expression in zebraﬁsh occurs after
the midblastula transition at the 512-cell stage [27]; therefore
expression seen before this stage indicates the presence of maternal
transcript. All genes were expressed throughout subsequent
development.
In situ hybridization analysis of gene expression
We next investigated the expression patterns of these genes by in
situ hybridization. A limited amount of in situ expression data for
dystroglycan (Dag1) has previously been reported [16]; therefore, we
used an equivalent probe in this study to compare the patterns of
these glycosylation genes directly to dystroglycan. To generate probes
for in situ hybridization, RT-PCR products for each gene were cloned
into the pGEM-T-Easy vector (primers used and probe sizes are
detailed in Table 2). For each probe, at least three independent in situ
hybridization experiments were performed using embryos from
stages between one cell and 35 h postfertilization (hpf). Representa-
tive embryos for each probe are shown in Figs. 3 and 4.
We saw expression of Dag1 in a pattern that was consistent with
the published data [16]. Staining was ﬁrst present at the one-cell stage
and Dag1 expression was then ubiquitous until 50% epiboly.
Transcripts were then restricted to the midline (chordamesoderm)and by the tailbud stage expression was seen only in the chordame-
soderm and in the head. At the eight-somite stage, staining was
present in the presomitic mesoderm and adaxial cells (Fig. 3). At later
stages of somitogenesis, positive staining for all these genes was
located in the position of the developing brain and eye and in the
muscle of the tail. By 30 hpf, Dag1 expression was predominant in the
forebrain, midbrain, otic vesicle, eye, muscle (particularly in the
vertical myosepta), and ﬁn, with low levels of mRNA in the cloaca
(Fig. 4).
The expression patterns of Large, POMT1, POMT2, POMGnT1,
Fukutin, and FKRP during early embryogenesis all resemble that of
Dag1 (Fig. 3). These genes are widely expressed, resulting in a very
broad and diffuse staining pattern. For each gene, a corresponding
sense control probe gave little or no background (Fig. 3), indicating
that this pattern was unlikely to be due to nonspeciﬁc staining.
Consistent with the RT-PCR data, we saw staining at very early stages
that is likely to represent maternal transcripts. Ubiquitous, low
expression was observed throughout epiboly and into somitogenesis.
For POMGnT1 and Fukutin, a signiﬁcant increase in transcript levels
was observed in the embryonic shield (Fig. 3). Large and POMT2 gave a
stronger signal along the embryo midline after 50% epiboly, although
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stages of somitogenesis, positive staining for all these genes was
located in the position of the developing eye and in the muscle of the
tail; for POMGnT1 expression appeared strongest within the myo-
tomes (Fig. 3).
At 30 hpf, the patterns of Large, POMT1, POMT2, POMGnT1, Fukutin,
and FKRP expression were also similar. Transcripts were observed in
the majority of the brain region, with strong staining seen in the
forebrain, cerebellum, and hindbrain (Fig. 4). POMGnT1 expression
appears higher in muscle than in brain. Other structures showing
staining were the eye, otic vesicle, and ﬁnbuds, and there was diffuse
staining throughout the tail region. Stronger signals were seen at the
vertical myosepta of the muscle (most apparent for POMT2), but no
expression was observed in the notochord.
In contrast to the other genes examined in this study, a very
distinct embryonic expression pattern was seen for Large2. There was
no visible maternal expression, in line with the very weak RT-PCR
ampliﬁcation at very early stages. Large2 expressionwas ﬁrst detected
at shield stage (in a pattern similar to that of POMGnT1 and Fukutin)
and then extended along the midline in the chordamesoderm and in
the adaxial cells during epiboly (Fig. 3). By 90% epiboly, staining was
also present in the anterior neural tissue. At the tailbud stage,
transcripts were detected in the presomitic mesoderm and the
tailbud. This expression pattern was maintained until about the ﬁve-
or six-somite stage. From this time point, presomitic mesoderm
stainingwas gradually lost and very strong expression appeared in the
presumptive pronephric duct. By 30 hpf, staining was conﬁned to the
lens, pronephric duct, cerebellum, otic vesicle, ﬁn, and tailbud (Fig. 4).
Little or no staining was detected in other parts of the CNS or the
mature tail muscle.
Localization of α- and β-dystroglycan during zebraﬁsh development
Previous immunohistochemistry studies have used only antibodies
against the β-DG subunit to assess dystroglycan protein distribution in
zebraﬁsh [16,18]. The monoclonal antibodies IIH6 and VIA41 speciﬁ-
cally recognize glycosylated epitopes of α-DG and lose reactivity in
dystroglycanopathy patient samples and the Largemyd mouse
[reviewed in 28]. To assess how glycosylated forms of α-DG are
distributed in zebraﬁsh, the distribution of VIA41 and IIH6 immunor-
eactivity was determined and compared to that for β-DG.
A monoclonal antibody against β-DG (NCL-b-DG) showed a weak
but reproducible signal on whole-mount staining of 30-hpf embryos.
Areas showing localization were brain (particularly the cerebellum),
eye (retina and lens), and muscle (including stronger staining at the
vertical myosepta), and weak staining of the cloaca was seen (Fig. 5).
This concentration of protein at themyosepta, which form the anterior
and posterior borders of the myotomes, is typically seen for
components of the zebraﬁsh DGC [16,18,19]. VIA41 recognizes only
functionally glycosylated α-DG in human and mouse [29,30]. On
zebraﬁsh embryos (30 hpf) this antibody showed a localization
pattern similar to that of β-DG, with strong signals in brain, eye,
muscle, and pronephric duct (Fig. 5).
The IIH6 antibody, which also recognizes only glycosylated forms
of α-DG [30,31], showed an overlapping but distinct pattern of
localization. The IIH6 epitope was most strongly expressed in lens,
pronephros/pronephric duct, otic vesicle, and cerebellum (Fig. 5A).
With longer staining times immunoreactivity was seen in muscle,
where IIH6 immunoreactivity was localized to the vertical and
horizontal myosepta (Fig. 5A), in a pattern similar to that for the
other dystroglycan antibodies. We then used a previously publishedFig. 3. In situ hybridization in early zebraﬁsh development. Genes used are labeled accordin
and developmental stage is assigned according to [36]. Developmental structures are labeled
eye; es, embryonic shield; f, ﬁn; im, intermediate mesoderm; l, lens; m, muscle/myotome; p,
tailbud. Scale bars, 250 μm.MO against Dag1 [16] to investigate the speciﬁcity of this staining for
α-DG. IIH6 staining (including that in the pronephros and pronephric
duct) was lost in Dag1 morphants showing the typical “kinked tail”
phenotype of this morpholino (Fig. 5B).
The distribution of IIH6 immunostaining is strikingly similar to the
pattern for Large2 mRNA expression, suggesting that in zebraﬁsh
Large2 may have a particular relationship to generation of the IIH6
epitope. To start to address this question we used AUG-blocking and
splice-site MOs directed against Large2 (Table 3). Injection of the AUG-
MO at doses of 5–10 ng/embryo produced a severe disruption of
development; similar effects were produced with the AUG-MM
mismatch morpholino (Fig. 5B), suggesting a nonspeciﬁc effect.
Lowering the dose to 2.5 ng/embryo resulted in distortion of the
trunk and edema around the heart (Fig. 5B), while 1.25 ng/embryo
produced a mild edema and distortion of the tail in only some
embryos. However, similar phenotypes were also seen with the AUG-
MM mismatch morpholino, suggesting that these are also probably
nonspeciﬁc effects. Embryos injected with the Large2 E2-MO (which
targets the splice junction at the 3′ end of the second coding exon)
showed no strong morphological abnormalities, except for distortion
of the trunk at a dose of 10 ng/embryo.
IIH6 reactivity was lost following injection of the Large2 AUG-MO
or E2-MOs, but not the control AUG-MM morpholino, even at high
doses of the latter that resulted in abnormal development (Fig. 5B).
Although some morphant embryos were observed with normal IIH6
staining (b5%), this was not dose dependent and was therefore likely
to be due to inefﬁciency of injection. We were not able to test for
knockdown of Large2 protein, due to the lack of a speciﬁc antibody.
For the E2-MO, the effect on splicing was tested by RT-PCR. However,
RT-PCR of RNA from MO-injected embryos failed to amplify Large2
(data not shown). The integrity of morphant RNA and ﬁrst-strand
cDNA was conﬁrmed using Ef1α primers; therefore it is possible that
the shortened form is efﬁciently degraded through nonsense-
mediated decay.
Discussion
We have demonstrated that the genes required for functional
glycosylation of dystroglycan are all present in zebraﬁsh, suggesting
that this very speciﬁc glycan pathway is highly conserved and not
conﬁned to mammals. Conservation of POMT1, POMT2, and
POMGnT1 indicates that O-mannosyl glycans are likely also to exist
in this organism. Teleost ﬁsh are thought to have undergone a
genome duplication event before the radiation of these species [32];
therefore it was surprising that no extra copies of any these genes
were found, even after further extensive BLAST searches of the
genome using the zebraﬁsh proteins. In a previous study, we also
found single copies of Large and Large2 in zebraﬁsh [25]. This
absence of ﬁsh-speciﬁc duplications may indicate that a high level of
control is necessary for correct glycosylation of α-DG and that
additional functional gene copies are not easily tolerated. The lack of
additional copies of dystroglycanopathy-associated genes also
increases the suitability of the zebraﬁsh as a research tool for
investigation of these genes.
The exon sizes of the dystroglycanopathy-associated genes are
well conserved between zebraﬁsh and humans. The detailed
conﬁrmation of sequence and exon structure provides data for
design of both splice-site and start-codon directed morpholino
oligonucleotides that will aid knockdown of these zebraﬁsh proteins
in future research. The data also provide evidence for the 5′ and 3′
limits of the genes, which would be useful in identifying potentialgly, “Sense” indicates appropriate sense control probe. Embryo orientation is indicated
: ac, adaxial cells; b, brain; cb, cerebellum; cm, chordamesoderm; dm, dorsal midline; e,
pineal; pn, pronephros; pnd, pronephric duct; psm, presomitic mesoderm; s, somite; tb,
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Fig. 5. Immunohistochemistry analysis of dystroglycan in 30-hpf embryos. (A) Immunohistochemistry of dystroglycan in 30-hpf wild-type zebraﬁsh embryos using the monoclonal
antibody NCL-b-DG, VIA41, or IIH6. cb, cerebellum; l, lens; ov, otic vesicle; pn, pronephros; pnd, pronephric duct; tc, telencephalon; vm, vertical myosepta. Scale bars, 250 μm.
(B) Immunohistochemistry using IIH6 in 26- to 30-hpf morphant embryos (as labeled). Immunostaining with this antibody is lost in the Dag1 and Large2 morphants, but not in the
Large2 AUG mismatch control. Black arrowheads represent presumed nonspeciﬁc staining around the eye. Key as for (A).
165C.J. Moore et al. / Genomics 92 (2008) 159−167promoter regions and external regulatory elements such as enhancer
or repressor sequences.
We examined the expression patterns of all these genes using in
situ hybridization and found that almost all of them appeared to be
coexpressed with dystroglycan. This is in agreement with the
hypothesis that dystroglycan is the primary target for these
glycosylation proteins. The presence of maternal transcripts for most
of these genes also indicates there might be a functional requirement
for glycosylated dystroglycan in the very early development of
zebraﬁsh. At later embryonic stages expression of these genes is
most prominent in the CNS, eyes, and muscle, tissues that are
predominantly affected in dystroglycanopathies. Large2 expression is
more restricted, with expression in the developing muscle, lens,
cerebellum, and pronephric duct. Interestingly, the regions of
expression of zebraﬁsh Large2 seem to be associated with cell
movement and morphogenesis; lens, somite, and pronephric duct
formation; and involution of cells at the embryonic shield. Whether
Large2 has an essential role in these processes is unclear. However,
further detailed investigation of these processes in morphants or
zebraﬁsh knockouts may be worthwhile.Fig. 4. In situ hybridization at 30 hpf. Genes used are labeled accordingly, all embryos are 30 h
hindbrain; l, lens; m, muscle/myotome; ov, otic vesicle; p, pineal: pn, pronephros; pnd, prone
bars, 250 μm.The very different expression patterns seen for zebraﬁsh Large and
Large2 show parallels to data that have been published on the mouse
and human genes [25,33,34]. Large is expressed broadly in mamma-
lian tissues but its highest levels are seen in tissues linked to the
common symptoms involved in dystroglycanopathies, i.e., muscle,
brain, and eye. Large2 shows a more restricted expression in mouse
and human, with little or no mRNA in mature muscle and the CNS but
high levels in the kidney. These parallels in expression patterns
indicate that the proteins may have similar roles in the zebraﬁsh.
Two monoclonal antibodies raised against glycosylated α-DG
(VIA41 and IIH6) have distinct but overlapping localization patterns
in zebraﬁsh embryos of 30 hpf, indicating that they are probably
directed at different epitopes. These two antibodies have been used
fairly interchangeably in many human and mouse studies because
they both recognize a functionally glycosylated form of α-DG that is
lost in dystroglycanopathies. In the immunohistochemistry data
reported here VIA41 is localized in a pattern reminiscent of the
mRNAs of dystroglycanopathy-associated genes and Dag1, whereas
IIH6 localization is more similar to the more restricted expression
pattern seen for Large2.pf. Developmental structures are labeled: cb, cerebellum; cl, cloaca; f, ﬁn; fb, ﬁnbud; hb,
phric duct; r, retina; t, tectum; tb, tailbud, tc, telencephalon; vm, vertical myosepta. Scale
Table 3
Morpholino oligonucleotides
MO Sequence (5′–3′) Description
Large2 AUG-MO GGC AGA GCA TCC TGG GAT TGT GGA G Translation blocking
Large2 AUG-MM GGG AGA GGA TCC AGG GTT TGT CGA G 5-bp mismatch control for
translation blocking
Large2 E2-MO CTC AAT AAA TGC CAA CTA ACC TCA C Splice blocking (exon 2
splice donor)
Sequences of the morpholino oligonucleotides used in this study. The mismatch bases
are in italic.
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Consistent with our expression data, dystroglycan has recently been
shown to be highly expressed in the Xenopus pronephros and to play
an important role in development of this organ [35]. Loss of this
staining was seen in morphant zebraﬁsh embryos for Dag1, conﬁrm-
ing that IIH6 is recognizing α-DG in this tissue. IIH6 staining was also
lost in two independent morphants for Large2, demonstrating that the
gene is required for production of this epitope on dystroglycan in
zebraﬁsh.
Thus, we have demonstrated that an essential dystroglycan
glycosylation pathway is conserved in zebraﬁsh, implying that the
glycan structures that are necessary forα-DG ligand binding activity are
also conserved. Our ﬁndings indicate that the zebraﬁsh is a usefulmodel
system for functional studies of these muscular dystrophy genes.
Materials and methods
Identiﬁcation of zebraﬁsh genes
The zebraﬁsh Fukutin, FKRP, POMGnT1, POMT1, and POMT2 genes
were identiﬁed by TBLASTN searches of the zebraﬁsh genome
assembly with the human amino acid sequence followed by NIX
analysis of genomic hits. For each zebraﬁsh orthologue, the coding
sequence was conﬁrmed by RT-PCR; products were then cloned into
pGEM-T-Easy (Promega) and sequenced.
Phylogenetic analysis of POMT1 and POMT2
Amino acid sequences were aligned with ClustalX, using the
Gonnet PAM 250 matrix because of its suitability for aligning
sequences with unknown or variable levels of divergence [36].
Alignments were then edited using SeqPup. A neighbor-joining tree
was created in ClustalX from the edited alignment. All gapped
residues, as well as regions of the alignment where the sequences
were too diverged to be sure that the alignment was correct, were
excluded from the input sequence.
RT-PCR
RNA was isolated from batches of staged embryos using Trizol
(Invitrogen). First-strand synthesis was performed using the ImProm
II ﬁrst-strand synthesis kit (Promega). Pairs of primers were designed
to amplify RT-PCR products of approximately 200 bp. They were also
designed so that any genomic product would be at least 1 kb and easily
distinguishable from the RT-PCR product. PCR primers and annealing
temperatures are listed in Table 2.
In situ hybridization and immunohistochemistry
Adult zebraﬁsh were maintained at Nottingham according to UK
HomeOfﬁce regulations. Lights were on a 24-h cyclewith 14 h light and
10 h dark. Staging of embryos was carried out by examination with a
dissecting microscope. Identiﬁcation of morphological structures and
overall body shape were used for staging [37]. To generate in situ
hybridization probes, RT-PCR products for each gene were cloned intothe pGEM-T-Easy vector (primers used and probe sizes are detailed in
Table 2). Plasmids were linearized and RNA was transcribed in the
presence of digoxigenin-labeled NTPs using T7 or Sp6 RNA polymerase,
as appropriate. In situ hybridization was carried out according to [38],
but using BM-purple (Roche) as an alternative to BCIP/NBT. For
immunohistochemistry, ﬁxed embryos were blocked at room tempera-
ture for 30min in blocking solution [38]. The blocking solutionwas then
replaced with block containing the primary antibody and the embryos
were incubated overnight at 4°C. Antibodies used were NCL-b-G
(Novocastra) at a dilution of 1:200, IIH6 (Upstate) at a dilution of
1:500, and VIA41 (Upstate) at a dilution of 1:500. Embryoswerewashed
6× for 15 min each in PBS containing 0.1% Tween (PBSTw), transferred
into blocking solution containing horseradish peroxidase-conjugated
secondary antibody, and incubated at 4°C overnight. Following washes
in PBSTw, antibody detection was performed using diaminobenzidine
stain (Vector Laboratories).
Microinjection of morpholino oligonucleotides
Antisense MOs were targeted to bind to pre-mRNA splice sites or
AUG initiation codons in mRNA. MOs were designed and manufac-
tured by Gene Tools, USA. MO (1.25–10 ng) dissolved in water was
injected into each one- to eight-cell (b1.25 hpf) embryo in a volume of
0.25–1 nl. Injections were performed using a glass ﬁlament needle
mounted on an MM-33 micromanipulator (Marhauzer) and driven by
a PicoSprizerIII air delivery system (Intracel). Drop-size calculation
and injections were viewed on a Stemi SV 6 dissecting microscope
(Zeiss) with KL 1500 LCD cold light source (Schott) uplighting.
Embryos were incubated at 28.5°C for 24–30 h. The MO sequence
and experimental conditions for the Dag1 MO were as given in [16].
The sequences of the two MOs targeted against Large2 are provided in
Table 3.
Image capture and analysis
Embryos were transferred to 75% glycerol in PBSTw via 25 and 50%
glycerol in PBSTw. Photographs were taken using a Nikon SMZ1500
microscope, a Nikon DS-5M camera, a Nikon DS-U1 control unit, and a
PC running Nikon ACT-2U 1.40 software. Images were prepared for
ﬁgures using Adobe Photoshop 5.5.
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